Morales MAY, Cisneros PDA, López MAL, Tovar FR

Language: Spanish
References: 31
Page: 89-93
PDF size: 144.27 Kb.

ABSTRACT

Androgenetic alopecia (AGA), commonly known as male pattern baldness, is the most common type of progressive hair loss disorder in men, and the main reason for dermatological consultation. aga features a progressive miniaturization of the hair follicle; its incidence and prevalence depends on age and ethnicity. The treatments available are minoxidil and oral treatment with 5-alpha reductase inhibitors (finasteride, dutasteride) but results are observed in a long-term period, plus, they depend on the patient’s attachment and often tend to be discontinued. That’s why research must now aim at developing treatments with better results. The efficacy of dutasteride in mesotherapy has been studied since 2008, nevertheless, it has demonstrated excellent outcomes, there is no uniformity among the application therapy protocols.
Objective: the objective of the present article is to describe the outcomes of five male patients with AGA classified as IV to VI in the Hamilton-Norwood scale, treated with dutasteride microinjections.
Methods: a retrospective study was conducted, it included five patients who were diagnosed with aga. All of them were treated with 1 ml of intradermal dutasteride at 0.01% during six months with one-session treatment every three months. Simultaneously, they received topical therapy using minoxidil. Assesment of the response was done using both, photographs and the Hamilton-Norwood scale.
Results: all patients increased the diameter of the existing hair and no side effects were reported.
Conclusion: dutasteride in mesotherapy proves to be an alternative for treating Mexicans with aga and outcomes can be evaluated in the mid-term.

REFERENCES

1. Hamilton JB, Patterned loss of hair in man: types and incidence, Ann N Y Acad Sci, 53: 708-28.

2. Severi G, Sinclair R, Hopper JL, English DR, McCredie MRE, Boyle P y Giles GG, Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors, Br J Dermatol, 149: 1207-13.

3. Hanneken S, Ritzmann S, Nothen MM et al., Androgenetic alopecia: current aspects of a common phenotype, Hautarzt 2003; 54(8):703-12.

4. Cash TF, The psychology of hair loss and its implications for patient care, Clin Dermatol 2001; 19(2):161-6.

5. Ellis JA, Sinclair R y Harrap SB, Androgenetic alopecia: pathogenesis and potential for therapy, Expert Rev Mol Med 2002; 4(22):1-11.

6. Nyholt DR, Gillespie NA, Heath AC y Martin NG, Genetic basis of male pattern baldness, J Invest Dermatol 2003; 121:1561-4.

7. Kuster W y Happle R, The inherinance of common baldness: two b or ot two b?, J Am Acad Dermatol 1984; 11:921-6.

8. Bergfeld WF, Androgenetic alopecia: an autosomal dominant disorder, Am J Med 1995: 95-98.

9. Ellis JA, Stebbing M y Harrap SB, Genetic analysis of male pattern baldness and the 5-alpha reductase genes, J Invest Dermatol 1998; 110(6):849-53.

10. Birch MP y Messenger AG, Genetic factors predispose to balding and non balding in men, Eur J Dermatol 2001; 11:309-14.

11. Kaufman KD, Androgens and alopecia, Mol Cell Endocrinol 2002; 198(1-2):89-95.

12. Imperato-McGinley J y Zhu YS, Androgens and male physiology the syndrome of 5-alpha reductase-2 deficency, Mol Cell Endocrinol 2002; 198(1-2):51-9.

13. Hamada K y Randall VA, Inhibitory autocrine factors produce by the mesenchyme derived hair follicle dermal papilla may be a key to male pattern baldness, Br J Dermatol 2006; 154(4):609-18.

14. Sawaya ME y Price VH, Different levels of 5-alpha reductase type i and ii, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia, J Invest Dermatol 1997; 109:296

15. Sawaya ME, Steroid chemistry and hormone controls during the harir follicle cycle, Ann NY Acad Sci 1991; 642:376.

16. Schmidt JB, Lindamaier A y Spona J, Hormonal parameters in androgenetic hair loss in the male, Dermatologica 1991; 182:214.

17. Rittmaster RS, Finasteride, N Engl J Med 1994; 330:120.

18. Mella JM, Perret MC y Manzotti M et al., Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review, Arch Dermatol 2010; 146:1141.

19. Kaufman KD, Olsen EA, Whiting D et al., Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group, J Am Acad Dermatol 1998; 39:578.

20. Finasteride Male Pattern Hair Loss Study Group, Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia, Eur J Dermatol 2002; 12:38.

21. Amory JK, Wang C, Swerdloff RS et al., The effect of 5-alpha reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men, J Clin Endocrinol Metab 2007; 92:1659.

22. Samplaski MK, Lo K, Grober E y Jarvi K, Finasteride use in the male infertility population: effects on semen and hormone parameters, Fertil Steril 2013; 100:1542.

23. Messenger AG y Rundegren J, Minoxidil: mechanisms of action on hair growth, Br J Dermatol 2004; 150:186-7.

24. Olsen EA y Weiner MS, Topical minoxidil in male pattern baldness: effects of discontinuation of treatment, J Am Acad Dermatol 1987; 17:97-98.

25. Ebner H y Müller E, Allergic contact dermatitis from minoxidil, Contact Dermatitis 1995; 32:316.

26. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML et al., The importance of dual 5-alpha reductasa inhibition in the treatment of male pattern hair loss: results of a randomized, double blind, placebo- controlled, phase iii study of dutasteride vs finasteride, J Am Acad Dermatol 2006; 55:1014-23.

27. Busanello EB y Turcatel E, Androgenetic alopecia and dutasteride in hair mesotherapy: a short review, Our Dermatol Online 2017; 9(1):75-9.

28. Abdallah M, El-Zawahry K y Besar H, Mesotherapy using dutasteride- containing solution in male pattern hair loss: a controlled pilot study, pald 2009; 20:137-45.

29. Sobhy N, Aly H, El Shafee A y El Deeb M, Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males, Our Dermatol Online 2013; 4(1): 40-5.

30. Saceda-Corralo D, Rodrigues-Barata A, Vañó-Galván S y Jaén-Olasolo P, Mesotherapy with dutasteride in the treatment of androgenetic alopecia, Int J Trichology 2017; 9(3):143-5.

31. Moftah N, Abd-Elaziz G, Ahmed N, Hamed Y y Ghannam B, Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometrsic and ultrastructural evaluation, J Eur Acad Dermatol Venereol 2013; 27(6):686-93.